Valsartan Teva

Valsartan

Essential HTN. Recent MI (12 hr-10 days) in clinically stable patient w/ symptomatic heart failure or asymptomatic left ventricular systolic dysfunction.

Adult HTN 80 mg once daily, may be increased to 160 mg up to a max 320 mg. Further BP reduction may be achieved by adding thiazide diuretic. Recent MI Initially 20 mg bd, then titrated to 40 mg, 80 mg & 160 mg bd over the next few wk. Max dose: 160 mg bd. Patient w/ mild to moderate hepatic impairment Should not exceed 80 mg.

May be taken with or without food.

Hypersensitivity. Severe hepatic impairment, biliary cirrhosis & cholestasis. Severe renal impairment (CrCl <10 mL/min) & patient undergoing dialysis. Concomitant use w/ aliskiren-containing products in patient w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Pregnancy & lactation.

Patients w/ aortic & mitral stenosis, or obstructive hypertrophic cardiomyopathy; pre-existing renal dysfunction or those w/ severe cardiac insufficiency; mild to moderate non-cholestatic hepatic impairment; heart failure. Evaluate renal function in post-MI patients. Correct Na &/or vol depletion prior to treatment initiation. Concurrent use of K supplements, K-sparing diuretics, K-containing salt substitutes or other medicinal products that may increase K levels (eg, heparin); frequently monitor K levels. Concurrent use w/ captopril is not recommended. Dual blockade of renin-angiotensin-aldosterone system through the combined use of ACE inhibitors, ARBs or aliskiren is not recommended. Should not be used in patients w/ primary hyperaldosteronism. Safety of valsartan use in patients w/ bilateral renal artery stenosis or stenosis to a solitary kidney has not been demonstrated. No experience w/ respect to safety of valsartan use in patients after recent kidney transplantation. May affect ability to drive & use machines. Not recommended during 1st trimester of pregnancy. Lactating mothers should not breastfeed while on treatment. Not recommended for use in childn <18 yr.

Patients w/ post-MI &/or heart failure: Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment. Patients w/ HTN: Uncommonly, vertigo; cough; abdominal pain; fatigue.

Increased K level w/ K supplements, K-sparing diuretics, K-containing salt substitutes. Increased antihypertensive effect w/ other antihypertensive agents. Attenuated antihypertensive effect w/ NSAIDs [eg, selective COX-2 inhibitors, ASA (>3 g daily) & non-selective NSAIDs]. Increased risk of worsening of renal function w/ NSAIDs. Higher frequency of adverse events w/ combined use of ACE inhibitors, ARBs or aliskiren. Potential reversible increases in lithium serum conc & toxic effects.

Angiotensin II Antagonists

C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

P₁S₁S₃